前列地尔治疗急性脑梗死

目的 :观察前列地尔 (脂微球制剂 )治疗急性脑梗死临床疗效。方法 :98例急性脑梗死病人分为 2组 ,其中前列地尔组 5 8例 ,男性 32例 ,女性 2 6例 ,年龄 62a±s 9a(4 6～ 80a) ,应用前列地尔 10μg ,iv ,qd ;川芎嗪组 4 0例 ,男性 2 4例 ,女性 16例 ,年龄 61a± 9a(4 4～ 82a) ,应用川芎嗪 2 0 0mg ,iv ,gtt ,qd ,2组疗程均为 15d。结果 :治疗后临床神经功能缺损评分前列地尔组 6.9分± 2 .4分 ,川芎嗪组 4 .4分± 1.9分 ;生活能力状态评价分别为 1.7分± 0 .6分和 1.5分± 0 .7分 ,组间比较差异无显著意义 (P >0 .0 5 )。但 2组治疗前后比较差异有非常显著意义 (P <0 .0 1)。结论 :前列地尔治疗急性脑梗死具有较好的疗效

Alprostadil in treatment of acute cerebral infarction

AIM: To observe the effect of alprostadil (lipoprostaglandine E 1) in the treatment of acute cerebral infarction. METHODS: Ninety eight patients with acute cerebral infarction were divided into two groups. Alprostadil group ( n =58) M 32,F 26; age 62 a± s 9 a(46～80 a)] was treated with alprostadil 10 μg, iv, qd for 15. Ligustrazine group ( n =40) M 24,F 16;age 61 a±9 a(44～82 a)] was treated with ligustrazine 200 mg, iv, gtt, qd, for 15 d. RESULTS: There was a significant difference ( P <0.01) for the nerve function deficiency between the alprostadil group (6.9±2.4) and the ligustrazine group (4.4±1.9) after treatment. Meanwhile, there was a strongly significant difference for the living ability between the alprostadil group (1.7±0.6) and the ligustrazine group (1.5±0.7) after treatment ( P <0.01). CONCLUSION: Alprostadil is an effective drug for decreasing nerve function deficiency and improving living ability in patients with acute cerebral infarction.